Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019 by Hedyeh Ebrahimi (7321358)

“…Trends were estimated from 1990 to 2019, with an emphasis on the 2010–19 period.</p><p><br></p><h3>Findings</h3><p dir="ltr">Globally, there were 2·26 million (95% uncertainty interval 2·07 to 2·45) new cases of tracheal, bronchus, and lung cancer, and 2·04 million (1·88 to 2·19) deaths and 45·9 million (42·3 to 49·3) DALYs due to tracheal, bronchus, and lung cancer in 2019. …”

Temporal patterns of cancer burden in Asia, 1990–2019: a systematic examination for the Global Burden of Disease 2019 study by Rajesh, Sharma

Get full text
Get full text
Get full text

The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017 by Arash Etemadi (330880)

“…Findings In 2017, more than 1·22 million (95% UI 1·19–1·25) incident cases of stomach cancer occurred worldwide, and nearly 865 000 people (848 000–885 000) died of stomach cancer, contributing to 19·1 million (18·7–19·6) DALYs. …”

High flow nasal oxygen (HFNO) in the treatment of COVID-19 infection of adult patients from – An emergency perspective: A systematic review and meta-analysis by Nabil, Shallik

“…HFNO was associated with a significant decrease in mortality and intubation rates (0.28 (95% CI; 0.19, 0.39) and 0.28 (95% CI; 0.18, 0.41), respectively). …”
Get full text
Get full text
Get full text

High flow nasal oxygen (HFNO) in the treatment of COVID-19 infection of adult patients from – An emergency perspective: A systematic review and meta-analysis by Nabil Shallik (15900256)

“…HFNO was associated with a significant decrease in mortality and intubation rates (0.28 (95% CI; 0.19, 0.39) and 0.28 (95% CI; 0.18, 0.41), respectively). …”

Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of... by Saeid Safiri (3713035)

“…</p><h3>Results</h3><p dir="ltr">Globally, there were 524 000 bladder cancer incident cases (95% uncertainty interval 476 000 to 569 000) and 229 000 bladder cancer deaths (211 000 to 243 000) in 2019. …”

The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global B... by Saeid Safiri (3713035)

“…Colorectal cancer was also responsible for 19·0 million (18·5–19·5) DALYs globally in 2017, with an age-standardised rate of 235·7 (229·7–242·0) DALYs per 100 000 person-years, which decreased between 1990 and 2017 (−14·5% [–20·4 to −10·3]). …”

The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global... by Farin Kamangar (63964)

“…Countries with a low SDI and HAQ Index and high levels of indoor air pollution had a higher proportion of oesophageal squamous cell carcinoma to all oesophageal cancer cases than did countries with a high SDI and HAQ Index and with low levels of indoor air pollution. …”

Trends in the global, regional, and national burden of oral conditions from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021 by Eduardo, Bernabe

Get full text
Get full text
Get full text

Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 by Brittney S Sheena (9715568)

“…</p><h3>Methods</h3><p dir="ltr">The primary data sources were population-based <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/serosurvey" target="_blank">serosurveys</a>, claims and hospital discharges, <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/cancer-registry" target="_blank">cancer registries</a>, vital registration systems, and published case series. …”

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments by Gunjan Dagar (9339276)

“…CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma by targeting CD-19 and B-cell maturation antigens. …”